Trials / Completed
CompletedNCT01452906
A Drug-Drug Interaction Study of Omeprazole and PA21
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Vifor Pharma · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if Omeprazole is affected by PA21.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 and Omeprazole with food | The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day |
| DRUG | No PA21; Omeprazole with food | The maximum dosage of Omeprazole will be 40 mg/day |
| DRUG | PA21 with food, Omeprazole 2hrs later | The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-10-17
- Last updated
- 2011-12-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01452906. Inclusion in this directory is not an endorsement.